ALKS 3831

Schizophrenia, bipolar

Stage (next event)

Expected Date

Resubmit NDA


Catalyst Info & Data Links

Mechanism of Action


  • ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. ALKS 3831 is composed of samidorphan, a novel, new molecular entity, co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.

Updated by MV

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See what the community is saying - click to see full post

ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co

ALKS Amp Update & Upcoming Catalysts

Investors Are Missing An Opportunity With Alkermes

AMP Inaugural Quarter (Q4 '16) Postmortem

AMP BioResearch Releases its Q1 2017 Company Picks

3Q2016 Hedge Fund Activity Related to AMP Portfolio companies

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon